- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02744768
D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia
D-ALBA Front-Line Sequential Treatment of Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients With Dasatinib and the Bispecific Monoclonal Antibody Blinatumomab
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Paola Fazi
- Phone Number: +39 06.70390521
- Email: p.fazi@gimema.it
Study Locations
-
-
-
Ascoli Piceno, Italy
- Not yet recruiting
- U.O.C. Ematologia e Terapia Cellulare - Ospedale "C. e G. Mazzoni" di Ascoli Piceno
-
Avellino, Italy
- Not yet recruiting
- Az.Ospedaliera S.G.Moscati
-
Contact:
- Nicola Cantore
-
Principal Investigator:
- Nicola Cantore
-
Bari, Italy
- Not yet recruiting
- UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro
-
Contact:
- Giorgina Specchia
-
Principal Investigator:
- Giorgina Specchia
-
Bergamo, Italy
- Recruiting
- Azienda Ospedaliera - Papa Giovanni XXIII
-
Contact:
- Alessandro Rambaldi
-
Principal Investigator:
- Alessandro Rambaldi
-
Bologna, Italy
- Not yet recruiting
- Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi
-
Contact:
- Giovanni Martinelli
-
Principal Investigator:
- Giovanni Martinelli
-
Brindisi, Italy
- Not yet recruiting
- Divisione di Ematologia Ospedale A. Perrino
-
Contact:
- Angela Melpignano
-
Principal Investigator:
- Angela Melpignano
-
Catania, Italy
- Recruiting
- Università di Catania - Cattedra di Ematologia - Ospedale "Ferrarotto"
-
Firenze, Italy
- Not yet recruiting
- Unità di Ricerca e di Malattie del sangue - Ematologia San Luca Vecchio Pad. 16 - 1° Piano
-
Contact:
- Alberto Bosi
-
Genova, Italy
- Not yet recruiting
- Unità Operative Complesse di Ematologia 1 e 2 Centro Trapianti di Midollo dell'IRCCS AOU San Martino-IST
-
Contact:
- Angelo Michele Carella
-
Principal Investigator:
- Angelo Michele Carella
-
Lecce, Italy
- Not yet recruiting
- ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE
-
Principal Investigator:
- Nicola Di Renzo
-
Mestre, Italy
- Recruiting
- U.O. di Ematologia- Ospedale dell'Angelo - Mestre
-
Principal Investigator:
- Renato Bassan
-
Contact:
- Renato Bassan
-
Milano, Italy
- Recruiting
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia- Padiglione Marcora 2° piano
-
Contact:
- Agostino Cortelezzi
-
Principal Investigator:
- Agostino Cortelezzi
-
Milano, Italy
- Not yet recruiting
- Ospedale Niguarda " Ca Granda" - SC Ematologia Blocco SUD, Ponti Est, Scala E, 4° piano
-
Contact:
- Valentina Mancini
-
Principal Investigator:
- Valentina Mancini
-
Napoli, Italy
- Recruiting
- Azienda Ospedaliera di Rilievo Nazionale "A. Cardarelli"
-
Contact:
- Felicetto Ferrara
-
Principal Investigator:
- Delicetto Ferrara
-
Napoli, Italy
- Recruiting
- Azienda Ospedaliera Universitaria - Università degli Studi di Napoli "Federico II" - Facoltà di Medicina e Chirurgia
-
Novara, Italy
- Recruiting
- S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro
-
Principal Investigator:
- Gianluca Gaidano
-
Orbassano, Italy
- Recruiting
- Dip. di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga-Medicina Interna 2
-
Contact:
- Giovanna Rege
-
Principal Investigator:
- Giovanna Rege
-
Pagani, Italy
- Recruiting
- U.O. di Oncoematologia -plesso ospedaliero "A. Tortora" di Pagani
-
Contact:
- Castello Califano
-
Principal Investigator:
- Castello Califano
-
Palermo, Italy
- Recruiting
- Ospedali Riuniti "Villa Sofia-Cervello"
-
Contact:
- Francesco Fabbiano
-
Principal Investigator:
- Francesco Fabbiano
-
Perugia, Italy
- Recruiting
- Sezione di Ematologia ed Immunologia Clinica - Ospedale S.Maria della Misericordia
-
Contact:
- Brunangelo Falini
-
Principal Investigator:
- Brunangelo Falini
-
Pescara, Italy
- Not yet recruiting
- Ematologia Clinica - Azienda USL di Pescara
-
Contact:
- Paolo Di Bartolomeo
-
Principal Investigator:
- Paolo Di Bartolomeo
-
Reggio Calabria, Italy
- Not yet recruiting
- Dipartimento Emato-Oncologia A.O."Bianchi-Melacrino-Morelli"
-
Contact:
- Francesca Ronco
-
Principal Investigator:
- Francesca Ronco
-
Roma, Italy
- Recruiting
- Complesso Ospedaliero S. Giovanni Addolorata
-
Contact:
- Anna Chierichini
-
Principal Investigator:
- Anna Chierichini
-
Roma, Italy
- Recruiting
- Università Cattolica del Sacro Cuore - Policlinico A. Gemelli
-
Contact:
- Simona C Sica
-
Roma, Italy
- Not yet recruiting
- Università degli Studi - Policlinico di Tor Vergata
-
Contact:
- Adriano Venditti
-
Principal Investigator:
- Adriano Venditti
-
Roma, Italy
- Not yet recruiting
- UOC Medicina Trasfusionale e Cellule Staminali Azienda Ospedaliera San Camillo Forlanini
-
Contact:
- Stefano C Mancini
-
Principal Investigator:
- Stefano Mancini
-
Rome, Italy
- Not yet recruiting
- Policlinico Umberto I, Hematology Department
-
Rome, Italy
- Recruiting
- Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia
-
Rozzano, Italy
- Not yet recruiting
- Sezione di Ematologia Cancer Center Humanitas
-
Contact:
- Matteo Della Porta
-
Principal Investigator:
- Matteo Della Porta
-
San Giovanni Rotondo, Italy
- Not yet recruiting
- Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza
-
Torino, Italy
- Not yet recruiting
- Dipartimento di Oncologia ed Ematologia S.C. Ematologia 2 A.O. Città della Salute e della Scienza di Torino San Giovanni Battista
-
Torino, Italy
- Not yet recruiting
- Struttura Complessa a Dir. Universitaria-Ematologia e Terapie Cellulari- A.S.O. Ordine Mauriziano, P.O. Umberto I-Ospedale Torino
-
Contact:
- Alessandro Cignetti
-
Principal Investigator:
- Alessandro Cignetti
-
Torino, Italy
- Not yet recruiting
- Struttura Complessa a Dir. Universitaria-Ematologia e Terapie Cellulari- A.S.O. Ordine Mauriziano, P.O. Umberto I-Ospedale
-
Contact:
- Alessandro Cignetti
-
Principal Investigator:
- Alessandro Cignetti
-
Verona, Italy
- Recruiting
- Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi
-
Contact:
- Massimiliano Bonifacio
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Newly diagnosed adult B-precursor Ph+ ALL patients.
- Age greater or equal to18 years,
- Signed written informed consent according to ICH/EU/GCP and national local laws.
- ECOG Performance Status 0 or 1 and/or WHO performance status less or equal to 2.
Renal and hepatic function as defined below:
- AST (GOT), ALT (GPT), and AP <2 x upper limit of normal (ULN).
- Total bilirubin <1.5 x ULN.
- Creatinine clearance equal or greater than 50 mL/min.
Pancreatic function as defined below:
- Serum amylase less or equal to 1.5 x ULN
- Serum lipase less or equal to1.5 x ULN.
- Normal cardiac function.
- Negative HIV test, negative HBV DNA and HCV RNA.
- Negative pregnancy test in women of childbearing potential.
- Bone marrow specimen from primary diagnosis available.
Exclusion Criteria:
- History of or current relevant CNS pathology (current ≥grade 2 epilepsy, seizure, paresis, aphasia, clinically relevant apoplexia, severe brain injuries, dementia, Parkinson's disease, organic brain syndrome, psychosis).
Impaired cardiac function, including any one of the following:
- LVEF <45% as determined by MUGA scan or echocardiogram.
- Complete left bundle branch block.
- Use of a cardiac pacemaker.
- ST depression of >1mm in 2 or more leads and/or T wave inversions in 2 or more contiguous leads.
- Congenital long QT syndrome.
- History of or presence of significant ventricular or atrial arrhythmia.
- Clinically significant resting bradycardia (<50 beats per minute).
- QTc >450 msec on screening ECG (using the QTcF formula).
- Right bundle branch block plus left anterior hemiblock, bifascicular block.
- Myocardial infarction within 3 months prior to starting Dasatinib.
- Angina pectoris.
- Other clinically significant heart disease (e.g., congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen).
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of Dasatinib (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
- History of or current autoimmune disease.
- Systemic cancer chemotherapy within 2 weeks prior to study.
- Known hypersensitivity to immunoglobulins or to any other component of the study drug formulation.
- Active malignancy other than ALL with the exception of basal cell or squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix.
- Active infection, any other concurrent disease or medical conditions that are deemed to interfere with the conduct of the study as judged by the investigator.
- Nursing women or women of childbearing potential not willing to use an effective form of contraception during participation in the study and at least 3 months thereafter or male patients not willing to ensure effective contraception during participation in the study and at least three months thereafter.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Adult Ph+ ALL (≥18 years old, with no upper age limit) patients will begin treatment with Dasatinib, 140 mg/day, from day 1 to day +84. Prednisone (PDN) will be administered from day -6 to day +0 (during which the presence of the BCR/ABL1 alteration will be established), at escalating doses up to 60 mg/m2; PDN will be continued up to day +24 and progressively tapered up to day +31. HLA typing will be performed immediately after the diagnosis for eligible patients. MRD will be evaluated by RT-PCR at fixed time points (days +22, +45, +57) during the induction and at day +85, the latter for molecular response evaluation. |
Adult Ph+ ALL (≥18 years old, with no upper age limit) patients will begin treatment with Dasatinib, 140 mg/day, from day 1 to day +84.
Upon induction: patients in CHR will receive Blinatumomab at a dose of 15 µg/m²/day as continuous intravenous infusion (CIVI) at a constant flow rate for four weeks, followed by a two-week infusion-free interval, defined as one treatment cycle. At least 2 cycles should be administered, up to a maximum of 5 cycles, if deemed necessary. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients who achieve Minimal Residual Disease (MRD) negativity upon treatment
Time Frame: After 11 months from study entry
|
In particular, after 2 cycles of blinatumomab.
Minimal Residual Disease (MRD) negativity is intended as Complete Molecular Remission (CMR)
|
After 11 months from study entry
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients completing the 2 cycles of blinatumomab and alive in first complete hematologic remission (CHR)
Time Frame: From day +85 at 12 months
|
From day +85 at 12 months
|
Number of patients at Complete Molecular Response (CMR)
Time Frame: At day +22, +45, +57 and +85 from study entry
|
At day +22, +45, +57 and +85 from study entry
|
Number of months of the CMR
Time Frame: At 12 and 24 months
|
At 12 and 24 months
|
Number of patients in Overall Survival (OS)
Time Frame: At 12 and 24 months
|
At 12 and 24 months
|
Number of grade >3 adverse events
Time Frame: At 12 and 24 months
|
At 12 and 24 months
|
Collaborators and Investigators
Investigators
- Study Chair: Roberto Foà, Policlinico Umberto I, Hematology Department.
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphoid
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Blinatumomab
- Dasatinib
Other Study ID Numbers
- LAL2116
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Lymphoblastic Leukemia
-
National Cancer Institute (NCI)CompletedB-cell Adult Acute Lymphoblastic Leukemia | Acute Undifferentiated Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingAcute Lymphoblastic Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Adult T Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Adult L1 Acute Lymphoblastic Leukemia | Adult L2 Acute Lymphoblastic...United States
-
Autolus LimitedCompletedCD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (AMELIA)Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia | Refractory Childhood Acute Lymphoblastic LeukemiaUnited Kingdom
-
Children's Oncology GroupNational Cancer Institute (NCI); ImmunoGen, Inc.WithdrawnRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | Refractory Mixed Phenotype Acute Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent...
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia | Non-T, Non-B Childhood Acute Lymphoblastic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Graft Versus Host Disease | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia
-
University College, LondonNot yet recruitingAcute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved Remission
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedB-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | Intermediate Risk Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, Switzerland
-
University of BirminghamAstraZeneca; Cancer Research UKTerminatedAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia RecurrentUnited Kingdom, Denmark, Netherlands
-
Therapeutic Advances in Childhood Leukemia ConsortiumEnzon Pharmaceuticals, Inc.TerminatedLymphoblastic Leukemia, Acute, Childhood | Leukemia, Lymphoblastic, Acute | Lymphoblastic Leukemia, Acute | Leukemia, Lymphoblastic, Acute, T CellUnited States, Australia
Clinical Trials on Dasatinib
-
Bristol-Myers SquibbCompletedPharmacokinetic Study in Healthy ParticipantsUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Completed
-
National Cancer Institute (NCI)WithdrawnHematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell MyelomaUnited States
-
Hyoung Jin KangNot yet recruitingAcute Lymphoblastic Leukemia, Pediatric
-
National Cancer Institute (NCI)NRG OncologyTerminatedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Recurrent Uterine Corpus CancerUnited States
-
Xspray Pharma ABQPS Bioserve India Pvt LimitedCompleted
-
Peking University Cancer Hospital & InstituteUnknownGastrointestinal Stromal TumorChina
-
Kanto CML Study GroupUnknownMyelogenous Leukemia, Chronic, Chronic PhaseJapan
-
Jonsson Comprehensive Cancer CenterBristol-Myers SquibbCompleted
-
Swiss Group for Clinical Cancer ResearchCompletedGastrointestinal Stromal TumorFrance, Switzerland, Germany, Finland